{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:15:19Z","timestamp":1783401319253,"version":"3.54.6"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s10067-026-08100-3","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:55:22Z","timestamp":1775523322000},"page":"3853-3864","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Potential of chimeric antigen receptor (CAR) T cell immunotherapy in systemic lupus erythematosus (SLE)"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8602-0958","authenticated-orcid":false,"given":"Ian C.","family":"Chikanza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Katsiari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7670-3314","authenticated-orcid":false,"given":"Lazaros I.","family":"Sakkas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,7]]},"reference":[{"key":"8100_CR1","doi-asserted-by":"crossref","unstructured":"Tsokos GC (2011) Systemic lupus erythematosus. N Engl J Med 365(22):2110\u20132121","DOI":"10.1056\/NEJMra1100359"},{"issue":"9","key":"8100_CR2","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1056\/NEJMra071297","volume":"358","author":"A Rahman","year":"2008","unstructured":"Rahman A, Isenberg DA (2008) Systemic lupus erythematosus. N Engl J Med 358(9):929\u2013939","journal-title":"N Engl J Med"},{"issue":"10","key":"8100_CR3","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1191\/0961203302lu273oa","volume":"11","author":"M Petri","year":"2002","unstructured":"Petri M (2002) Sex hormones and systemic lupus erythematosus. Lupus 11(10):661\u2013662","journal-title":"Lupus"},{"issue":"3","key":"8100_CR4","doi-asserted-by":"crossref","DOI":"10.1186\/ar1942","volume":"13","author":"T D\u00f6rner","year":"2011","unstructured":"D\u00f6rner T, Giesecke C (2011) Autoimmunity and B cell targeting in systemic lupus erythematosus. Arthritis Res Ther 13(3):245","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"8100_CR5","first-page":"1","volume":"17","author":"VR Moulton","year":"2015","unstructured":"Moulton VR, Tsokos GC (2015) Abnormalities of T cell signaling in systemic lupus erythematosus. Arthritis Res Ther 17(1):1\u201311","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"8100_CR6","doi-asserted-by":"publisher","first-page":"5459","DOI":"10.4049\/jimmunol.1002795","volume":"192","author":"MK Crow","year":"2014","unstructured":"Crow MK (2014) Type i interferon in the pathogenesis of lupus. J Immunol 192(12):5459\u20135468","journal-title":"J Immunol"},{"issue":"5","key":"8100_CR7","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1177\/1759720X11415456","volume":"3","author":"W Xiong","year":"2011","unstructured":"Xiong W, Lahita RG (2011) Novel treatments for systemic lupus erythematosus. Ther Adv Musculoskelet Dis 3(5):255\u2013266","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"8100_CR8","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1056\/NEJMoa2410965","volume":"392","author":"RA Furie","year":"2025","unstructured":"Furie RA, Rovin BH, Garg JP, Santiago MB, Aroca-Mart\u00ednez G, Zuta Santill\u00e1n AE et al (2025) Efficacy and safety of obinutuzumab in active lupus nephritis. N Engl J Med 392:1471\u20131483","journal-title":"N Engl J Med"},{"issue":"6","key":"8100_CR9","first-page":"e421","volume":"3","author":"RA Furie","year":"2021","unstructured":"Furie RA (2021) Efficacy and safety of litifilimab in patients with cutaneous lupus erythematosus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Rheumatol 3(6):e421\u2013e431","journal-title":"Lancet Rheumatol"},{"key":"8100_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2024.110200","volume":"263","author":"E Papachristodoulou","year":"2024","unstructured":"Papachristodoulou E, Kyttaris VC (2024) New and emerging therapies for systemic lupus erythematosus. Clin Immunol 263:110200","journal-title":"Clin Immunol"},{"issue":"8","key":"8100_CR11","first-page":"913","volume":"31","author":"J Huang","year":"2022","unstructured":"Huang J, Li X, Wang Y (2022) Chimeric antigen receptor T-cell therapy targeting B-cells in systemic lupus erythematosus. Lupus 31(8):913\u2013919","journal-title":"Lupus"},{"issue":"Suppl 2","key":"8100_CR12","first-page":"A96","volume":"9","author":"alfa Efavaleukin","year":"2022","unstructured":"Efavaleukin alfa (2022) A novel IL-2 mutein, selectively expands regulatory t cells in patients with SLE: final results of a phase 1b multiple ascending dose study. Lupus Sci Med 9(Suppl 2):A96\u2013A97","journal-title":"Lupus Sci Med"},{"key":"8100_CR13","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/B978-0-443-13947-5.00007-5","volume-title":"Regulatory T cells and autoimmune diseases","author":"IC Chikanza","year":"2024","unstructured":"Chikanza IC, Trollip S, Sakkas LI (2024) Regulatory T cells and autoimmunity MK Dwivedi D Fairweather Eds Regulatory T cells and autoimmune diseases Academic. Press 41-56"},{"key":"8100_CR14","doi-asserted-by":"crossref","unstructured":"Cort\u00e9s-Hern\u00e1ndez J, Ignatenko S, Gordienko A et al (2023) Safety and efficacy of subcutaneous dose ianalumab (VAY736; anti-BAFF-R mAb) administered monthly over 28 weeks in patients with systemic lupus erythematosus (SLE). Ann Rheum Dis 82(Suppl 1):275.2","DOI":"10.1136\/annrheumdis-2023-eular.3110"},{"key":"8100_CR15","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.imlet.2023.06.005","volume":"260","author":"TD Steinmetz","year":"2023","unstructured":"Steinmetz TD, Verstappen GM, Suurmond J, Kroese FGM (2023) Targeting plasma cells in systemic autoimmune rheumatic diseases: promises and pitfalls. Immunol Lett 260:44-57","journal-title":"Immunol Lett"},{"issue":"4","key":"8100_CR16","doi-asserted-by":"crossref","first-page":"e227","DOI":"10.1016\/S2665-9913(20)30036-9","volume":"2","author":"EF Morand","year":"2020","unstructured":"Morand EF (2020) Anifrolumab in adults with moderate-to-severe active systemic lupus erythematosus (TULIP-2): a randomised, controlled, phase 3 trial. Lancet Rheumatol 2(4):e227-e239","journal-title":"Lancet Rheumatol"},{"issue":"3","key":"8100_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26030929","volume":"26","author":"K Saegusa","year":"2025","unstructured":"Saegusa K, Tsuchida K, Komai T, Tsuchiya H, Fujio K (2025) Advances in targeted therapy for systemic lupus erythematosus: current treatments and novel approaches. Int J Mol Sci 26(3):929","journal-title":"Int J Mol Sci"},{"issue":"Suppl 3","key":"8100_CR18","volume":"11","author":"R Furie","year":"2024","unstructured":"Furie R (2024) Bi-specific antibodies. Lupus Sci Med 11(Suppl 3):A16","journal-title":"Lupus Sci Med"},{"issue":"12","key":"8100_CR19","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1002\/art.42652","volume":"75","author":"JT Merrill","year":"2023","unstructured":"Merrill JT, Guthridge J, Smith M, June J, Koumpouras F, Machua W (2023) Obexelimab in systemic lupus erythematosus with exploration of response based on gene pathway co-expression patterns: a double-blind, randomized, placebo-controlled, phase 2 trial. Arthritis Rheumatol 75(12):2185\u20132194","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"8100_CR20","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/art.42391","volume":"75","author":"E Morand","year":"2023","unstructured":"Morand E, Pike M, Merrill JT (2023) Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: a phase, randomized, double-blind placebo-controlled trial. Arthritis Rheumatol 75(2):242\u2013252","journal-title":"Arthritis Rheumatol"},{"key":"8100_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2025-005742","volume":"11","author":"JT Merrill","year":"2025","unstructured":"Merrill JT, Saxena A, Aringer M, Tanaka Y, Zeng X, Cheng L et al (2025) Efficacy and safety of upadacitinib as monotherapy or combined with elsubrutinib for the treatment of systemic lupus erythematosus: results through 104 weeks in a long-term extension study. RMD Open 11:e005742","journal-title":"RMD Open"},{"issue":"2","key":"8100_CR22","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/s41591-021-01657-3","volume":"28","author":"F M\u00fcller","year":"2022","unstructured":"M\u00fcller F, Ehlers M, Hartmann J (2022) CD19-targeted CAR T cells in refractory systemic lupus erythematosus. Nat Med 28(2):241\u2013248","journal-title":"Nat Med"},{"issue":"2","key":"8100_CR23","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1172\/JCI91081","volume":"127","author":"A Le","year":"2017","unstructured":"Le A, Abdel-Motal UM, Moudgil KD (2017) Engineering CAR T cells to regulate autoimmune responses. J Clin Invest 127(2):569\u2013580","journal-title":"J Clin Invest"},{"key":"8100_CR24","unstructured":"Tan T, Zhang J, Zhou X et al (2018) CD19-targeted CAR T cells in lupus-prone mice. Sci Transl Med. 10(464): eaan8912"},{"issue":"1","key":"8100_CR25","first-page":"33","volume":"29","author":"M Al-Haddad","year":"2020","unstructured":"Al-Haddad M, Chen Y, Wu H (2020) CAR T cells for lupus therapy: preclinical studies. Lupus 29(1):33\u201340","journal-title":"Lupus"},{"issue":"8","key":"8100_CR26","first-page":"1189","volume":"26","author":"S Liu","year":"2020","unstructured":"Liu S, Wang X, Li Y (2020) Modulating T-cell activation in autoimmune diseases with CAR T-cell therapy. Nat Med 26(8):1189\u20131197","journal-title":"Nat Med"},{"issue":"1","key":"8100_CR27","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1016\/S2665-9913(20)30359-3","volume":"3","author":"C Zhao","year":"2021","unstructured":"Zhao C, Li Y, Chen X (2021) Early clinical trials of CAR T-cell therapy for refractory. SLE Lancet Rheumatol 3(1):e16-e24","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"8100_CR28","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2024-001156","volume":"8","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, Wang H, Chen S (2021) A pilot study of CD19 CAR T-cell therapy in refractory systemic lupus erythematosus. Lupus Sci Med 8(1):e000505","journal-title":"Lupus Sci Med"},{"issue":"1","key":"8100_CR29","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ekir.2025.10.008","volume":"11","author":"Y Mao","year":"2025","unstructured":"Mao Y, Shen W, Shen J, Zhang C, An K, Tang Y (2025) Bicistronic-CD19\/22 chimeric antigen receptor T-cell therapy for childhood refractory lupus nephritis Kidney. Int Rep 11(1):53-61","journal-title":"Kidney Int Rep"},{"key":"8100_CR30","unstructured":"Wang D, Zhang Y, Liu H et al (2024) Safety and efficacy of CD19\/BCMA dual-target CAR-T cells in refractory systemic lupus erythematosus: an early exploratory phase 1 study. ClinTrials.gov. NCT05858684"},{"issue":"1","key":"8100_CR31","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","volume":"52","author":"VK Kuchroo","year":"2020","unstructured":"Kuchroo VK, Anderson AC, Petrovas C (2020) Future perspectives of CAR T-cell therapy in autoimmunity. Immunity 52(1):17-21","journal-title":"Immunity"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08100-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-026-08100-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08100-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T04:27:08Z","timestamp":1783398428000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-026-08100-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,7]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["8100"],"URL":"https:\/\/doi.org\/10.1007\/s10067-026-08100-3","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,7]]},"assertion":[{"value":"12 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}